This is a multicenter, double-masked study to evaluate the use of Topical Ocular BL1332 for the management of post-operative pain after Photorefractive Keratectomy (PRK) surgery.
Male or female 18 to 58 years of age, inclusive.
Scheduled to undergo PRK surgery and considered to be a good candidate per the Investigator's discretion.
Provide written informed consent (signed and dated informed consent form [ICF]) using the Institutional Review Board (IRB)-approved ICF prior to any study-related procedures.
Able to read, understand, and voluntarily sign the ICF and, if applicable, provide written authorization per local privacy regulations.
Women of childbearing potential or non-vasectomized males with partners of childbearing potential are not eligible unless they are using an effective method of contraception and agree to use an effective method of contraception until at least 30 days after study treatment.
Participation in a clinical trial within 30 days prior to Screening.
Parallel
Topical Ocular BL1332 low dose
DrugAdministered 5 times a day
Topical Ocular BL1332 high dose
DrugAdministered 5 times a day
BL1332 Vehicle ophthalmic vehicle
DrugAdministered 5 times a day
Ocular pain intensity following PRK surgery
Ocular pain intensity assessed using numeric pain rating scale 0 to 10, with 10 being the worst pain
Ocular pain intensity postoperative period following PRK surgery
Ocular pain intensity assessed using numeric pain rating scale 0 to 10, with 10 being the worst pain
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
